Novel inhibitors of glycation and AGE formation

Cell Biochemistry and Biophysics

Volumn 48, Issue 2-3, 2007, Pages 147-157

  Rahbar, Samuel ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Diabetes; Dyslipidemia; Glycation; Lipoxidation; Nephropathy; Oxidative stress

Indexed keywords

3 NITROTYROSINE; 3-NITROTYROSINE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; ANTIDIABETIC AGENT; ASCORBIC ACID; BUTYRIC ACID DERIVATIVE; CHOLESTEROL; CREATININE; DRUG DERIVATIVE; HYDROXYL RADICAL; IMMUNOGLOBULIN RECEPTOR; LOW DENSITY LIPOPROTEIN; LR 90; LR-90; PYRIDOXAL 5 PHOSPHATE; TRIACYLGLYCEROL; TYROSINE; UNCLASSIFIED DRUG;

ANIMAL; ARTICLE; BLOOD; BODY WEIGHT; CHEMICAL STRUCTURE; CHEMISTRY; DIABETIC NEPHROPATHY; DRUG ANTAGONISM; DRUG EFFECT; DYSLIPIDEMIA; EXPERIMENTAL DIABETES MELLITUS; GLYCOSYLATION; KIDNEY; LIPID METABOLISM; MALE; METABOLISM; OXIDATION REDUCTION REACTION; PATHOLOGY; RAT; SPRAGUE DAWLEY RAT; URINE;

ANIMALS; ASCORBIC ACID; BODY WEIGHT; BUTYRATES; CHOLESTEROL; CREATININE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DYSLIPIDEMIAS; GLYCOSYLATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HYDROXYL RADICAL; HYPOGLYCEMIC AGENTS; KIDNEY; LIPID METABOLISM; LIPOPROTEINS, LDL; MALE; MOLECULAR STRUCTURE; OXIDATION-REDUCTION; PYRIDOXAL PHOSPHATE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, IMMUNOLOGIC; TRIGLYCERIDES; TYROSINE;

ANIMALIA; RATTUS;

EID: 34548299920     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-007-0021-x     Document Type: Article

References (50)

1. Brownlee, M. (1995). Advanced protein glycosylation in diabetes and aging. Annual Review of Medicine, 46, 223-234.
2. Frye, B., Degenhardt, T. P., Thorpe, S. R., & Baynes, J. W. (1998). Role of Mailard reaction in aging of tissue proteins: age-dependent increase in imidazolium crosslinks in human lens protein. The Journal of Biological Chemistry, 273, 18714-18719.
3. Anderson, M. M., Requena, J. R., Crawley, J. R., Thorpe, S. R., & Heinecke, J. W. (1999). The myeloperoxidase system of human phagocytes generates Nepsilon-(carboxymethyl)lysine on proteins. The Journal of Clinical Investigation, 104, 103-113.
4. Munch, G., Shepherd, S. E., McCann, H., Brooks, W. S., Kwok, J. B., Arendt, T., Hallupp, M., Schofield, P. R., Martins, R. N., & Halliday, G. M. (2002). Intraneuronal advanced glycation endproducts is present in Alzheimer's disease. Neuroreport, 13, 601-604.
5. Stitt, A. W., He, C., Friedman, S., Scher, L., Rossi, P., Ong, L., Founds, H., Li, Y. M., Bucala, R., & Vlassara, H. (1997). Elevated AGE-modified ApoB in sera of euglycemic, normolipidemic patients with atherosclerosis: Relationship to tissue AGEs. Molecular Medicine, 3, 617-627.
6. Nagai, R., Hayashi, C. M., Xia, L., Takeya, M., & Horiuchi, S. (2002). Identification in human atherosclerotic lesions of GA-pyridine. The Journal of Biological Chemistry, 277, 48905-48912.
7. Baynes, J. W. (2002). The Maillard hypothesis on aging; time to focus on DNA. Annals of the New York Academy of Sciences, 959, 360-367.
8. Halliwell, B. (1989). Protection against tissue damage in vivo by desferrioxamine. Free Radicals in Biology and Medicine, 7, 645-651.
9. Berlett, B. S., & Stadtman, E. R. (1997). Protein oxidation in aging, disease and oxidative stress. The Journal of Biological Chemistry, 272, 20313-20316.
10. Thornally, P. J., Langborg, A., & Minhas, H. S. (1999). Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. The Biochemical Journal, 344, 109-116.
11. Ahmed, N. (2005). Advanced glycation endproducts-role in pathology of diabetic complications. Diabetes Research and Clinical Practice, 67, 3-21.
12. Vlassara, H., & Palace, M. R. (2002). Diabetes and advanced glycation endproducts. Journal of Internal Medicine, 251, 87-101.
13. Rojas, A., & Morales, M. A. (2004). Advanced glycation and endothelial functions: a link towards vascular complications in diabetes. Life Sciences, 76, 715-730.
14. Yamagishi, S., & Imaizumi, T. (2005). Diabetic vascular complications: Pathophysiology, biochemical basis and potential therapeutic strategy. Current Pharmaceutical Design, 11, 2279-2299.
15. Basta, G., Schmidt, A. M., & De Caterina, R. (2004). Advanced glycation end products and vascular inflammation: Implications for accelerated atherosclerosis in diabetes. Cardiovascular Research, 63, 582-592.
16. Jakus, V, & Rietbrock, N. (2004). Advanced glycation end-products and the progress of diabetic vascular complications. Physiological Research, 53, 1131-1142.
17. DeGroot, J. (2004). The AGE of the matrix: chemistry, consequence and cure. Current Opinion in Pharmacology, 4, 301-305.
18. Rosca, M. G., Mustata, T. G., Kinter, M. T., Oxdemir, A. M., Kern, T. S., Szweda, L. I., Brownlee, M., Monnier, V. M., & Weiss, M. F. (2005). Glycation of mitochondrial proteins from diabetic rat kidney is associated with excess superoxide formation. American Journal of Physiology. Renal Physiology, 289, F420-F430.
19. Schmidt, A. M., Hori, O., Brett, J., Yan, S. D., Wautier, J. L., & Stern, D. (1994). Cellular receptors for advanced glycation end-products: Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arteriosclerosis and Thrombosis, 14, 1521-1528.
20. Vlassara, H. (2001). The AGE-receptor in the pathogenesis of diabetic complications. Diabetes/Metabolism Research and Reviews, 17, 436-443.
21. Schmidt, A. M., Yan, S. D., Yan, S. F., & Stern, D. M. (2000). The biology of the receptor for advanced glycation end products and its ligands. Biochemistry and Biophysics, 1498, 99-111.
22. Kim, W., Hudson, B., Moser, B., Guo, J., Rong, L. L., Lu, Y., Qu, W., Lalla, E., Lerner, S., Chen, Y., Yan, S. S., D'Agati V., Naka, Y., Ramasamy, R., Herold, K., Yan, S. F., & Schmidt, A. M. (2005). Receptor for advanced glycation end products and its ligands: A journey from the complications of diabetes to its pathogenesis. Annals of the New York Academy of Sciences, 1043, 553-561.
23. Bucciarelli, L. G., Wendt, T., Rong, L. L., Goova, M. T., Moser, B., Kislinger, T., Lee, D. C., Kashyap, Y., Stern, D. M., & Schmidt, A. M. (2002). RAGE is a multiligand receptor of the immunoglobulin superfamily: Implications for homeostasis and chronic disease. Cellular and Molecular Life Sciences, 59, 1117-1128.
24. Basta, G., Lazzerini, G., Massaro, M., Simoncini, T., Tanganelli, P., Fu, C, Kislinger, T., Stern, D. M., Schmidt, A. M., & De Caterina, R. (2002). Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: A mechanism for amplification of inflammatory responses. Circulation, 105, 816-822.
25. Chavakis, T., Bierhaus, A., & Nawroth, P. P. (2004). RAGE (receptor for advanced glycation end products): A central player in the inflammatory response. Microbes and Infection, 6, 1219-1225.
26. Liliensiek, B., Weigand, M. A., Bierhaus, A., Nicklas, W., Kasper, M., Hofer, S., Plachky, J., Grone, H. J., Kurschus, F. C., Schmidt, A. M., Yan, S. D., Martin, E., Schleicher, E., Stern, D. M., Hammerling, G. G., Nawroth, P. P., Arnold, B. (2004). Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. The Journal of Clinical Investigation, 113, 1641-1650.
27. Wautier, J. L., & Schmidt, A. M. (2004). Protein glycation: A firm link to endothelial cell dysfunction. Circulation Research, 95, 233-238.
28. Ramasamy, R., Vannucci, S. J., Yan, S. S., Herold, K., Yan, S. F., & Schmidt, A. M. (2005). Advanced glycation end products and RAGE: A common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology, 15, 16R-28R.
29. Hudson, B. I., & Schmidt, A. M. (2005). RAGE: A novel target for drug intervention in diabetic vascular disease. Pharmaceutical Research, 21, 1079-1086.
30. Park, L., Raman, K. G., Lee, K. J., Lu, Y., Ferran, L. J. Jr., Chow, W. S., Stern, D., & Schmidt, A. M. (1998). Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nature Medicine, 4, 1025-1031.
31. Bucciarelli, L. G., Wendt, T., Qu, W., Lu, Y., Lalla, E., Rong, L. L., Goova, M. T., Moser, B., Kislinger, T., Lee, D. C., Kashyap, Y., Stern, D. M., & Schmidt, A. M. (2001). RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation, 106, 2827-2835.
32. Rong, L. L., Trojaborg, W., Qu, W., Kostov, K., Yan, S. D., Gooch, C., Szabolcs, M., Hays, A. P., & Schmidt, A. M. (2004). Antagonism of RAGE suppresses peripheral nerve regeneration. The FASEB Journal, 18, 11812-11817.
33. Marx, N., Walcher, D., Ivanova, N., Rautzenberg, K., Jung, A., Friedl, R., Hombach, V., de Caterina, R., Basta, G., Wautier, M. P., & Wautiers, J. L. (2004). Thiazolidinediones reduce endothelial expression of receptors for advanced glycation end products. Diabetes, 53, 2662-2668.
34. Rahbar, S., & Figarola, J. L. (2003). Novel inhibitors of advanced glycation endproducts. Archives of Biochemistry and Biophysics, 419, 63-79.
35. Figarola, J. L., Scott, S., Loera, S., Tessler, C., Chu, P., Weiss, L., Hardy, J., & Rahbar, S. (2001). LR-90 a new advanced glycation endproduct inhibitor prevents progression of diabetic nephropathy in streptozotocin- diabetic rats. Diabetologia, 46, 1140-1152.
36. Figarola, J. L., Scott, S., Loera, S., Xi, B., Synold, T., Weiss, L., & Rahbar, S. (2005). Prevention of early renal disease, dyslipidemia and lipid peroxidation in STZ-diabetic rats by LR-9 and LR-74, novel AGE inhibitors. Diabetes/Metabolism Research and Reviews, 21, 533-544.
37. Miyata, T., van Ypersele de Strihou, C., Ueda, Y., Ichimori, K., Inagi, R., Onogi, H., Ishikawa, N., Nangaku, M., & Kurokawa, K. (2002). Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: Biochemical mechanisms. Journal of the American Society of Nephrology, 13, 2478-2487.
38. Wolff, S. P. (1993). Diabetes mellitus and free radicals. Free radicals, transition metals and oxidative stress in the aetiology of diabetes mellitus and complications. British Medical Bulletin, 49, 642-652.
39. Kennedy, A. L., & Lyons, T. J. (1997). Glycation, oxidation, and lipoxidation in the development of diabetic complications. Metabolism, 46, 14-21.
40. Kim, W., Hudson, B., Moser, B., Guo, J., Rong, L.L., Lu, Y., Qu, W., Lalla, E., Lerner, S., Chen, Y., Yan, S. S., D'Agati V., Naka, Y., Ramasamy, R., Herold, K., Yan, S. F., & Schmidt, A. M. (2005). Receptor for advanced glycation end products and its ligands: A journey from the complications of diabetes to its pathogenesis. Annals of the New York Academy of Sciences, 1043, 553-561.
41. Yamamoto, Y., Kato, I., Doi, T., Yonekura, H., Ohashi, S., Takeuchi, M., Watanabe, T., Yamagishi, S., Sakurai, S., Takasawa, S., Okamoto, H., & Yamamoto, H. (2001). Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. The Journal of Clinical Investigation, 108, 261-268.
42. Wendt, T. M., Tanji, N., Guo, J., Kislinger, T. R., Qu, W., Lu, Y., Bucciarelli, L. G., Rong, L. L., Moser, B., Markowitz, G. S., Stein, G., Bierhaus, A., Liliensiek, B., Arnold, B., Nawroth, P. P., Stern, D. M., D'Agati V. D., & Schmidt, A. M. (2003). RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. The American Journal of Pathology, 162, 1123-1137.
43. Heidland, A., Sebekova, K., Schinzel, R. (2001). Advanced glycation end products and the progressive course of renal disease. American Journal of Kidney Diseases, 38, S100-S106.
44. Thuraisingham, R. C., Nott, C. A., Dodd, S. M., & Yaqoob, M. M. (2000). Increased nitrotyrosine staining in kidneys from patients with diabetic nephropathy. Kidney International, 57, 968-972.
45. Anderson, M. M., Requena, J. R., Crowley, J. R., Thorpe, S. R., & Heinecke, J. W. (1999). The myeloperoxidase system of human phagocytes generates N-epsilon(carboxymethyl)lysine on proteins: A mechanism for producing advanced glycation end products at sites of inflammation. The Journal of Clinical Investigation, 104, 103-113.
46. Kislinger, T., Fu, C., Huber, B., Qu, W., Taguchi, A., Du Yan, S., Hofmann, M., Yan, S. F., Pischetsrieder, M., Stern, D., & Schmidt, A. M. (1999). N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. The Journal of Biological Chemistry, 274, 31740-3174.
47. Basta, G., Lazzerini, G., Massaro, M., Simoncini, T., Tanganelli, P., Fu, C., Kislinger, T., Stern, D. M., Schmidt, A. M., & De Caterina, R. (2002). Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: A mechanism for amplification of inflammatory responses. Circulation, 105, 816-822.
48. Gu, L., Hagiwara, S., Fan, Q., et al. (2005). Role of receptor for advanced glycation end-products and signalling events in advanced glycation end-product-induced monocyte chemoattractant protein-1 expression in differentiated mouse podocytes. Nephrology, Dialysis, Transplantation, 21, 299-313.
49. Figarola, JL., Shanmugam, N., Natarajan, R., & Rahbar, S. (2007). Anti-inflammatory effects of the advanced glycation end product inhibitor LR-90 in human monocytes. Diabetes, 56, 647-655.
50. Degenhardt, T. P., Alderson, N. L., Arrington, D. D., Beattie, R. J., Basgen, J. M., Steffes, M. W., Thorpe, S. R., & Baynes, J. W. (2002). Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney International, 61, 939-950.